<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134563</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6049</org_study_id>
    <secondary_id>2004-000555-42</secondary_id>
    <secondary_id>HMR1726D/3001</secondary_id>
    <nct_id>NCT00134563</nct_id>
  </id_info>
  <brief_title>Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis</brief_title>
  <acronym>TEMSO</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to determine the effect of teriflunomide on the frequency of
      relapses in patients with relapsing multiple sclerosis (MS).

      Secondary objectives were:

        -  to evaluate the effect of teriflunomide on the accumulation of disability as measured by
           Expanded Disability Status Scale [EDSS], the burden of disease as measured by Magnetic
           Resonance Imaging [MRI] and patient-reported fatigue;

        -  to evaluate the safety and tolerability of teriflunomide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study period per participant was approximatively 128 weeks broken down as follows:

        -  Screening period up to 4 weeks,

        -  108-week double-blind treatment period (approximatively 2 years)*,

        -  16-week post-treatment elimination follow-up period.

      '*' Participants successfully completing the week 108 visit were offered the opportunity to
      enter the optional long-term extension study LTS6050 - NCT00803049.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</measure>
    <time_frame>108 weeks</time_frame>
    <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in EDSS score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 12-week Sustained Disability Progression: Kaplan-Meier Estimates of the Rate of Disability Progression at Timepoints</measure>
    <time_frame>108 weeks</time_frame>
    <description>12-week sustained disability progression was defined as an increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score &gt;5.5) that persisted for at least 12 weeks.
Probability of disability progression at 24, 48 and 108 weeks was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase. Participants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)</measure>
    <time_frame>baseline (before randomization) and 108 weeks</time_frame>
    <description>Total lesion volume is the sum of the total volume of all T2-lesions and the total volume all T1-hypointense post-gadolinium lesions measured through T2/proton density scan analysis and gadolinium-enhanced T1 scan analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Fatigue Impact Scale [FIS] Total Score</measure>
    <time_frame>baseline (before randomization) and 108 weeks</time_frame>
    <description>FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)</measure>
    <time_frame>108 weeks</time_frame>
    <description>Number of Gd-enhancing T1-lesions per scan is obtained from the total number of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.
To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as &quot;offset&quot; variable; treatment group, region of enrollment, baseline EDSS stratum and baseline number of Gd-enhancing T1-lesions as covariates).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan</measure>
    <time_frame>108 weeks</time_frame>
    <description>Total volume of Gd-enhancing T1-lesions per scan is obtained from the sum of the volumes of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1088</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 7 mg once daily for 108 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 14 mg once daily for 108 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Teriflunomide 7 mg</arm_group_label>
    <arm_group_label>Teriflunomide 14 mg</arm_group_label>
    <other_name>HMR1726</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for teriflunomide)</intervention_name>
    <description>Film-coated tablet
Oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple sclerosis [MS] subject who was ambulatory (EDSS of ≤ 5.5)

          -  Exhibiting a relapsing clinical course, with or without progression (relapsing
             remitting, secondary progressive or progressive relapsing);

          -  Meeting McDonald's criteria for MS diagnosis;

          -  Experienced at least 1 relapse over the 1 year preceding the trial or at least 2
             relapses over the 2 years preceding the trial;

          -  No relapse onset in the preceding 60 days prior to randomization;

          -  Clinically stable during the 30 days prior to randomization, without
             adrenocorticotrophic hormone [ACTH] or systemic steroid treatment.

        Exclusion Criteria:

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major
             systemic disease;

          -  Significantly impaired bone marrow function;

          -  Pregnant or nursing woman;

          -  Alcohol or drug abuse;

          -  Use of cladribine, mitoxantrone, or other immunosuppressant agents such as
             azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before
             enrollment;

          -  Any known condition or circumstance that would prevent in the investigator's opinion
             compliance or completion of the study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul O'Connor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital Toronto (Canada)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Austria</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis, Canada</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Denmark</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Finland</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Deutschland GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Poland</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Switzerland</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Turkey</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis UK</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.</citation>
    <PMID>21991951</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <results_first_submitted>October 3, 2012</results_first_submitted>
  <results_first_submitted_qc>October 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2012</results_first_posted>
  <disposition_first_submitted>August 8, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 8, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 15, 2011</disposition_first_posted>
  <last_update_submitted>January 2, 2013</last_update_submitted>
  <last_update_submitted_qc>January 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing Remitting</keyword>
  <keyword>Secondary Progressive</keyword>
  <keyword>Progressive Relapsing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment initiated in September 2004 was completed in February 2008.
A total of 1338 patients were screened at 127 sites in 21 countries.</recruitment_details>
      <pre_assignment_details>Randomization was stratified by country and baseline disability (Expanded Disability Status Scale [EDSS] score ≤3.5 or &gt;3.5).
Assignment to groups was done centrally using an Interactive Voice Response System (IVRS] in a 1:1:1 ratio after confirmation of the selection criteria.
1088 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
        </group>
        <group group_id="P2">
          <title>Teriflunomide 7 mg</title>
          <description>Teriflunomide 7 mg once daily for 108 weeks</description>
        </group>
        <group group_id="P3">
          <title>Teriflunomide 14 mg</title>
          <description>Teriflunomide 14 mg once daily for 108 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="363">Randomized</participants>
                <participants group_id="P2" count="366">Randomized</participants>
                <participants group_id="P3" count="359">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="363">Two participants received doses of Teriflunomide 7 mg, one participant doses of Teriflunomide 14 mg</participants>
                <participants group_id="P2" count="365"/>
                <participants group_id="P3" count="358">one participant received doses of Teriflunomide 7 mg</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="259">completed treatment period</participants>
                <participants group_id="P2" count="274">completed treatment period</participants>
                <participants group_id="P3" count="263">completed treatment period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated due to protocol violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not wish to continue</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason other than above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
        </group>
        <group group_id="B2">
          <title>Teriflunomide 7 mg</title>
          <description>Teriflunomide 7 mg once daily for 108 weeks</description>
        </group>
        <group group_id="B3">
          <title>Teriflunomide 14 mg</title>
          <description>Teriflunomide 14 mg once daily for 108 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="363"/>
            <count group_id="B2" value="365"/>
            <count group_id="B3" value="358"/>
            <count group_id="B4" value="1086"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics of the population included in analyses</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="9.0"/>
                    <measurement group_id="B2" value="37.5" spread="9.0"/>
                    <measurement group_id="B3" value="37.8" spread="8.2"/>
                    <measurement group_id="B4" value="37.9" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="254"/>
                    <measurement group_id="B3" value="254"/>
                    <measurement group_id="B4" value="783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of enrollment</title>
          <description>America: Canada, Chile, and United States;
Eastern Europe: Czech Republic, Estonia, Poland, Russia and Ukraine;
Western Europe: Austria, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Portugal, Sweden, Switzerland, Turkey, and United Kingdom;</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first diagnosis of multiple sclerosis (MS)</title>
          <description>The information was missing for one participant in the Teriflunomide 7 mg group.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.13" spread="5.59"/>
                    <measurement group_id="B2" value="5.29" spread="5.36"/>
                    <measurement group_id="B3" value="5.59" spread="5.44"/>
                    <measurement group_id="B4" value="5.33" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of MS relapses</title>
          <units>MS relapses</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Within the past year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="B2" value="1" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="B4" value="1" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Within the past 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="12"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="9"/>
                    <measurement group_id="B4" value="2" lower_limit="1" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since most recent MS relapse onset</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.28" spread="3.62"/>
                    <measurement group_id="B2" value="6.29" spread="3.29"/>
                    <measurement group_id="B3" value="6.50" spread="3.71"/>
                    <measurement group_id="B4" value="6.35" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MS subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Relapsing Remitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="332"/>
                    <measurement group_id="B4" value="993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Progressive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Relapsing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MS medication in the past 2 years</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="256"/>
                    <measurement group_id="B4" value="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline EDSS total score</title>
          <description>EDSS is an ordinal scale in half-point increments that qualifies disability in patients with MS. It consists of 8 ordinal rating scales assessing seven functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation.
EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤ 3.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="276"/>
                    <measurement group_id="B4" value="837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 3.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</title>
        <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in EDSS score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).</description>
        <time_frame>108 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily for 108 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily for 108 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate [ARR]: Poisson Regression Estimates</title>
          <description>ARR is obtained from the total number of confirmed relapses that occured during the treatment period divided by the sum of the treatment durations.
Each episode of relapse - appearance, or worsening of a clinical symptom that was stable for at least 30 days, that persisted for a minimum of 24 hours in the absence of fever - was to be confirmed by an increase in EDSS score or Functional System scores.
To account for the different treatment durations among participants, a Poisson regression model with robust error variance was used (total number of confirmed relapses as response variable; log-transformed treatment duration as &quot;offset&quot; variable; treatment group, region of enrollment and baseline EDSS stratum as covariates).</description>
          <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
          <units>relapses per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.539" lower_limit="0.466" upper_limit="0.623"/>
                    <measurement group_id="O2" value="0.370" lower_limit="0.318" upper_limit="0.432"/>
                    <measurement group_id="O3" value="0.369" lower_limit="0.308" upper_limit="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis:
H1: No difference between Teriflunomide 14 mg and placebo
H2: No difference between Teriflunomide 7 mg and placebo
The study was sized to detect a 25% relative risk reduction with teriflunomide in the 2-year relapse rate at a significance level of 0.050 with a power ≥95% anticipating a potential 20% 2-year dropout rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Step down approach used to adjust for multiplicity:
H1 tested first
H2 tested only if the comparison H1 was statistically significant
A priori threshold for statistical significance for both comparisons ≤0.05</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Relative risk reduction (%)</param_type>
            <param_value>31.5</param_value>
            <estimate_desc>Relative risk reduction with Teriflunomide 14 mg compared to placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Step down approach used to adjust for multiplicity:
H1 tested first
H2 tested only if the comparison H1 was statistically significant
A priori threshold for statistical significance for both comparisons ≤0.05</p_value_desc>
            <method>Regression, Poisson</method>
            <param_type>Relative Risk Reduction (%)</param_type>
            <param_value>31.2</param_value>
            <estimate_desc>Relative risk reduction with Teriflunomide 7 mg compared to placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 12-week Sustained Disability Progression: Kaplan-Meier Estimates of the Rate of Disability Progression at Timepoints</title>
        <description>12-week sustained disability progression was defined as an increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score &gt;5.5) that persisted for at least 12 weeks.
Probability of disability progression at 24, 48 and 108 weeks was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase. Participants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.</description>
        <time_frame>108 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily for 108 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily for 108 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 12-week Sustained Disability Progression: Kaplan-Meier Estimates of the Rate of Disability Progression at Timepoints</title>
          <description>12-week sustained disability progression was defined as an increase from baseline of at least 1-point in EDSS score (at least 0.5-point for participants with baseline EDSS score &gt;5.5) that persisted for at least 12 weeks.
Probability of disability progression at 24, 48 and 108 weeks was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase. Participants free of disability progression (no disability progression observed on treatment) were censored at the date of the last on-treatment EDSS evaluation.
Kaplan-Meier method consists in computing probabilities of non occurrence of event at any observed time of event and multiplying successive probabilities for time ≤t by any earlier computed probabilities to estimate the probability of being event-free for the amount of time t. Probability of event at time t is 1 minus the probability of being event-free for the amount of time t.</description>
          <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
          <units>percent probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Probability of disability progression at 24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="5.7" upper_limit="11.6"/>
                    <measurement group_id="O2" value="5.8" lower_limit="3.3" upper_limit="8.3"/>
                    <measurement group_id="O3" value="6.2" lower_limit="3.6" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probability of disability progression at 48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="12.1" upper_limit="20.0"/>
                    <measurement group_id="O2" value="13.1" lower_limit="9.4" upper_limit="16.7"/>
                    <measurement group_id="O3" value="11.3" lower_limit="7.9" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probability of disability progression at 108 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="22.3" upper_limit="32.3"/>
                    <measurement group_id="O2" value="21.7" lower_limit="17.1" upper_limit="26.3"/>
                    <measurement group_id="O3" value="20.2" lower_limit="15.6" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis:
H1: No difference between Teriflunomide 14 mg and placebo
H2: No difference between Teriflunomide 7 mg and placebo
The study was also sized to detect a 37% hazard rate reduction of an assumed disability progression hazard rate of 0.1783 in the placebo group and 0.1116 in the teriflunomide group by the end of 2 years with a power of 80% anticipating a potential 20% 2-year dropout rate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0279</p_value>
            <p_value_desc>Step down approach:
H1 tested only if both comparisons on the primary outcome measure were statistically significant
H2 tested only if the comparison H1 was statistically significant
A priori threshold for statistical significance ≤0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Two-sided Log-rank test stratified by region of enrollment and baseline EDSS stratum</method_desc>
            <param_type>Hazard ratio reduction (%)</param_type>
            <param_value>29.8</param_value>
            <estimate_desc>Relative risk reduction with Teriflunomide 14 mg compared to placebo (estimated from a Cox proportional hazard model with treatment arm, region of enrollment and baseline EDSS stratum as covariates)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0835</p_value>
            <p_value_desc>Step down approach:
H1 tested only if both comparisons on the primary outcome measure were statistically significant
H2 tested only if the comparison H1 was statistically significant
A priori threshold for statistical significance ≤0.05</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Two-sided Log-rank test stratified by region of enrollment and baseline EDSS stratum</method_desc>
            <param_type>Hazard ratio reduction (%)</param_type>
            <param_value>23.7</param_value>
            <estimate_desc>Relative risk reduction with Teriflunomide 7 mg compared to placebo (estimated from a Cox proportional hazard model with treatment arm, region of enrollment and baseline EDSS stratum as covariates)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)</title>
        <description>Total lesion volume is the sum of the total volume of all T2-lesions and the total volume all T1-hypointense post-gadolinium lesions measured through T2/proton density scan analysis and gadolinium-enhanced T1 scan analysis.</description>
        <time_frame>baseline (before randomization) and 108 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily for 108 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily for 108 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Magnetic Resonance Imaging [MRI] Assessment: Change From Baseline in Total Lesion Volume (Burden of Disease)</title>
          <description>Total lesion volume is the sum of the total volume of all T2-lesions and the total volume all T1-hypointense post-gadolinium lesions measured through T2/proton density scan analysis and gadolinium-enhanced T1 scan analysis.</description>
          <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
          <units>mililiters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in total lesion volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.208" spread="7.002"/>
                    <measurement group_id="O2" value="1.308" spread="6.799"/>
                    <measurement group_id="O3" value="0.723" spread="7.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Change in T1-hypointense lesion component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.533" spread="1.063"/>
                    <measurement group_id="O2" value="0.499" spread="1.154"/>
                    <measurement group_id="O3" value="0.331" spread="1.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- Change in T2-lesion component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.674" spread="6.473"/>
                    <measurement group_id="O2" value="0.810" spread="6.181"/>
                    <measurement group_id="O3" value="0.392" spread="6.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with repeated measures [MMRM] on cubic root transformed total lesion volume data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value (cubic root transformed) and baseline-by-visit interaction).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>A priori threshold for statistical significance ≤0.05
No adjustment for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>2-sided t-test on baseline adjusted least-square means</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mixed-effect model with repeated measures [MMRM] on cubic root transformed total lesion volume data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value (cubic root transformed) and baseline-by-visit interaction).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0317</p_value>
            <p_value_desc>A priori threshold for statistical significance ≤0.05
No adjustment for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>2-sided t-test on baseline adjusted least-square means</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)</title>
        <description>Number of Gd-enhancing T1-lesions per scan is obtained from the total number of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.
To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as &quot;offset&quot; variable; treatment group, region of enrollment, baseline EDSS stratum and baseline number of Gd-enhancing T1-lesions as covariates).</description>
        <time_frame>108 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily for 108 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily for 108 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral MRI Assessment: Number of Gd-enhancing T1-lesions Per Scan (Poisson Regression Estimates)</title>
          <description>Number of Gd-enhancing T1-lesions per scan is obtained from the total number of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.
To account for the different number of scans among participants, a Poisson regression model with robust error variance was used (total number of Gd-enhancing T1-lesions as response variable; log-transformed number of scans as &quot;offset&quot; variable; treatment group, region of enrollment, baseline EDSS stratum and baseline number of Gd-enhancing T1-lesions as covariates).</description>
          <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
          <units>lesions per scan</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.331" lower_limit="1.059" upper_limit="1.673"/>
                    <measurement group_id="O2" value="0.570" lower_limit="0.434" upper_limit="0.748"/>
                    <measurement group_id="O3" value="0.261" lower_limit="0.167" upper_limit="0.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan</title>
        <description>Total volume of Gd-enhancing T1-lesions per scan is obtained from the sum of the volumes of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.</description>
        <time_frame>108 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily for 108 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily for 108 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral MRI Assessment: Volume of Gd-enhancing T1-lesions Per Scan</title>
          <description>Total volume of Gd-enhancing T1-lesions per scan is obtained from the sum of the volumes of Gd-enhancing T1-lesions observed during the study divided by the total number of scans performed during the study.</description>
          <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
          <units>mililiters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="350"/>
                <count group_id="O3" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.102" spread="0.329"/>
                    <measurement group_id="O2" value="0.059" spread="0.247"/>
                    <measurement group_id="O3" value="0.025" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Fatigue Impact Scale [FIS] Total Score</title>
        <description>FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).</description>
        <time_frame>baseline (before randomization) and 108 weeks</time_frame>
        <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
          </group>
          <group group_id="O2">
            <title>Teriflunomide 7 mg</title>
            <description>Teriflunomide 7 mg once daily for 108 weeks</description>
          </group>
          <group group_id="O3">
            <title>Teriflunomide 14 mg</title>
            <description>Teriflunomide 14 mg once daily for 108 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Fatigue Impact Scale [FIS] Total Score</title>
          <description>FIS is a subject-reported scale that qualifies the impact of fatigue on daily life in patients with MS. It consists of 40 statements that measure fatigue in three areas; physical, cognitive, and social.
FIS total score ranges from 0 (no problem) to 160 (extreme problem).
Least-square means were estimated using a Mixed-effect model with repeated measures [MMRM] on FIS total score data (treatment group, region of enrollment, baseline EDSS stratum, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as factors).</description>
          <population>All randomized and treated participants; Participants were included in the treatment group to which they were originally assigned (intent-to-treat analysis).</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="365"/>
                <count group_id="O3" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.300" spread="1.670" lower_limit="-98" upper_limit="99"/>
                    <measurement group_id="O2" value="2.343" spread="1.641" lower_limit="-114" upper_limit="96"/>
                    <measurement group_id="O3" value="3.804" spread="1.670" lower_limit="-86" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8271</p_value>
            <p_value_desc>A priori threshold for statistical significance ≤0.05
No adjustment for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>2-sided t-test on baseline adjusted least-square means</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3861</p_value>
            <p_value_desc>A priori threshold for statistical significance ≤0.05
No adjustment for multiple comparisons</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>2-sided t-test on baseline adjusted least-square means</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AE) were collected regardless of seriousness or relationship to the drug, spanning from signature of the Informed Consent Form up to the last visit.</time_frame>
      <desc>The analysis was performed on the exposed population and included all AE that developed or worsened from first study drug intake up to 112 days after last intake or up to first intake in the extension study, whichever came first (124 weeks max).
Participants who received incorrect treatment were included considering the incorrect treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo (for teriflunomide) once daily for 108 weeks</description>
        </group>
        <group group_id="E2">
          <title>Teriflunomide 7 mg</title>
          <description>Teriflunomide 7 mg once daily for 108 weeks</description>
        </group>
        <group group_id="E3">
          <title>Teriflunomide 14 mg</title>
          <description>Teriflunomide 14 mg once daily for 108 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Intestinal functional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nuclear magnetic resonance imaging abdominal abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Facial nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Glossopharyngeal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Post abortion haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="265" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="360"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="368"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator can publish only the results of the work performed pursuant to this protocol. Prior to publication, the investigator provides the sponsor with the manuscript for review and comment at least 45 days in advance of its submission for publication.
The sponsor can require the investigator to withhold publication an additional 90 days to allow for filing a patent application or taking such other measures as sponsor deems appropriate to establish and preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact_US@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

